Richard J. Turner
Keine laufenden Positionen mehr
Karriereverlauf von Richard J. Turner
Ehemalige bekannte Positionen von Richard J. Turner
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Transcriptogen Ltd.
Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Direktor/Vorstandsmitglied | - | 17.06.2017 |
Vorstandsvorsitzender | - | 17.06.2017 | |
Catalyst Venture Partners Ltd.
Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Vorstandsvorsitzender | 29.04.2011 | - |
Gründer | 29.04.2011 | - | |
Private Equity Investor | 01.01.1999 | 01.09.2010 | |
Corporate Officer/Principal | 01.01.1999 | 29.04.2011 |
Statistik
International
Vereinigtes Königreich | 3 |
Operativ
Chief Executive Officer | 2 |
Founder | 1 |
Private Equity Investor | 1 |
Sektoral
Finance | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Catalyst Venture Partners Ltd.
Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Finance |
Transcriptogen Ltd.
Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Richard J. Turner
- Erfahrung